143 related articles for article (PubMed ID: 30319127)
41. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
Ruiz de Porras V; Font A; Aytes A
Cancer Lett; 2021 Dec; 523():162-169. PubMed ID: 34517086
[TBL] [Abstract][Full Text] [Related]
42. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
Parente P; Ng S; Parnis F; Guminski A; Gurney H
Asia Pac J Clin Oncol; 2017 Dec; 13(6):391-399. PubMed ID: 28488360
[TBL] [Abstract][Full Text] [Related]
43. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
44. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
[TBL] [Abstract][Full Text] [Related]
45. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
46. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A; Caffo O; De Giorgi U; Di Lorenzo G; Ortega C; Scognamiglio F; Aieta M; Facchini G; Mansueto G; Mattioli R; Procopio G; Zagonel V; D'Angelo A; Spizzo G; Bortolus R; Donini M; Lo Re G; Massari F; Vicario G; Zucali PA; Alesini D; Bonetti A; Mucciarini C; Nicodemo M; Berruti A; Fratino L; Lodde M; Messina C; Perin A; Santini D; Sava T; Tucci M; Basso U; Maines F; Burgio LS; Galligioni E
Future Oncol; 2016 Feb; 12(4):493-502. PubMed ID: 26776493
[TBL] [Abstract][Full Text] [Related]
48. Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
Cicero G; De Luca R; Dorangricchia P; Galvano A; Lo Re G; Serretta V; Dispensa N; Dieli F
Oncology; 2017; 92(2):94-100. PubMed ID: 27960186
[TBL] [Abstract][Full Text] [Related]
49. Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy.
Rizk R; Danse E; Aydin S; Tombal B; Machiels JP
Urol Int; 2014; 93(1):49-54. PubMed ID: 24296400
[TBL] [Abstract][Full Text] [Related]
50. Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Heidenreich A; Porres D; Piper C; Thissen AK; Pfister D
Minerva Urol Nefrol; 2013 Sep; 65(3):171-87. PubMed ID: 23872628
[TBL] [Abstract][Full Text] [Related]
51. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
52. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
54. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
55. Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Thiery-Vuillemin A; Fizazi K; Sartor O; Oudard S; Bury D; Ozatilgan A; Poole EM; Eisenberger M; de Bono J
Oncologist; 2021 Jul; 26(7):e1179-e1188. PubMed ID: 33904646
[TBL] [Abstract][Full Text] [Related]
56. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
Bahl A; Masson S; Malik Z; Birtle AJ; Sundar S; Jones RJ; James ND; Mason MD; Kumar S; Bottomley D; Lydon A; Chowdhury S; Wylie J; de Bono JS
BJU Int; 2015 Dec; 116(6):880-7. PubMed ID: 25639506
[TBL] [Abstract][Full Text] [Related]
57. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
[TBL] [Abstract][Full Text] [Related]
58. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
60. Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
de Wit R; Tombal B; Freedland S
Eur Urol; 2021 Feb; 79(2):170-172. PubMed ID: 33218827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
